Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 8Lymphoma, T-Cell, Cutaneous 6Leukemia, Lymphocytic, Chronic, B-Cell 6Melanoma 5Lymphoma, T-Cell, Peripheral 5Carcinoma, Ovarian Epithelial 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, Follicular 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Fallopian Tube Neoplasms 3Breast Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Kidney Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Turcot syndrome 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1

Interventions

mogamulizumab 4Lenalidomide 4Cyclophosphamide 3Gemcitabine 2Doxorubicin 2Alemtuzumab 2ruxolitinib 1peginterferon alfa-2b 1liposomal doxorubicin 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1dolutegravir 1denileukin diftitox 1cobomarsen 1brincidofovir 1belinostat 1Zidovudine 1Vincristine 1Tenofovir 1Taxes 1Raltegravir Potassium 1Prednisone 1Panobinostat 1Paclitaxel 1Oxaliplatin 1Lomustine 1Irinotecan 1Introns 1Interleukin-15 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia-Lymphoma, Adult T-Cell × denileukin diftitox × Clear all
NCT00117845 2019-11-19

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
17 enrolled 9 charts
LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡